Pharmaceutical Industry in
Bellinzona

Humabs BioMed SA

Since 2011 · 11–20 empl.

The core activity of Humabs BioMed SA is the discovery and development of anti-infective immunotherapies for the treatment of viral and bacterial diseases, including those caused by Zika, Ebola, Rabies, Dengue and other Flaviviruses. The company focuses on the development of therapeutics up to clinical proof of concept and has a broad pipeline of development candidates.

MADDOX Pharma Swiss GmbH

Since 2015 · 1–10 empl.

The core activity of Maddox Pharma Swiss is the development, manufacture and marketing of health products, particularly pharmaceuticals and dietary supplements, with the aim of improving people's quality of life and creating stakeholder value.

MV BioTherapeutics SA

Since 2018 · 11–20 empl.

The core activity of MV BioTherapeutics SA is the development and application of technologies for regulating the intestinal ecosystem in medical applications, particularly through the ApyraMed/ApyraVax platform. This platform enables the conditional regulation of the intestinal ecosystem to control the adaptive immune response and promote mutualism with intestinal commensals. The company focuses on developing solutions for medical applications, particularly in the fields of mucosal immunology and biomedicine.

Peptone Switzerland AG

Since 2022 · 21–50 empl.·3.0(2)

The core activity of Peptone is the development of small molecules for targeted treatment of intrinsically disordered proteins (IDPs) using Artificial Intelligence (AI) and experimental physics. The company focuses on the discovery and development of drugs that specifically target these proteins, which are responsible for many diseases.

ASKLEBIO Sagl

Since 2019 · 1–10 empl.

Dynalab Sagl

Since 2019 · 1–10 empl.

CHOOSE LIFE BIOTECH SA

Since 2021 · 1–10 empl.

MicThera Sagl

Since 2023 · 1–10 empl.